Onconova Therapeutics's competitors

Onconova Therapeutics's competitors include Provectus Biopharmaceuticals, Halozyme Therapeutics, Verastem and Exelixis
Add company...
Onconova Therapeutics
Onconova Therapeutics is a biopharmaceutical company developing small molecule drug candidates for the treatment of cancer.
Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies.
Halozyme Therapeutics
Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.
Verastem
Verastem is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells.
Exelixis
Exelixis a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.
Founding Date
Founding Date
1998
Founding Date
2002
Founding Date
1998
Founding Date
2012
Founding Date
1994
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Newtown, US HQ
Locations
Knoxville, US HQ
Locations
San Diego, US HQ
Locations
Needham, US HQ
Locations
South San Francisco, US HQ
Employees
Employees
23
Employees
4
Employees
259
Employees
32
Employees
287
Valuation ($)
Valuation ($)
29.1 m
Valuation ($)
13.2 m
Valuation ($)
2.6 b
Valuation ($)
350.2 m
Valuation ($)
6.2 b
Facebook likes
Facebook likes
N/A
Facebook likes
226
Facebook likes
71
Facebook likes
N/A
Facebook likes
N/A

Financial

Revenue (est.)
Revenue (est.)
$787k (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$146.7m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
$37.2m (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$33.2m (FY, 2016)
Cost of goods
N/A
Cost of goods
$3.9m (FY, 2016)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$113.5m (FY, 2016)
Gross profit
N/A
Gross profit
$33.3m (FY, 2016)
Net income
Net income
($24.1m) (FY, 2017)
Net income
($13.5m) (FY, 2017)
Net income
($103m) (FY, 2016)
Net income
($67.8m) (FY, 2017)
Net income
($169.7m) (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 88m
Total funding raised
N/A
Total funding raised
$ 113m
Total funding raised
$ 70m
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

Provectus Biopharmaceuticals
HQ
Knoxville, US
Employees
4

Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies.

View company
Halozyme Therapeutics
HQ
San Diego, US
Employees
259

Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.

View company
Verastem
HQ
Needham, US
Employees
32

Verastem is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells.

View company
Exelixis
HQ
South San Francisco, US
Employees
287

Exelixis a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.

View company